Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

416 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents for Primary PCI: A Subgroup Analysis of the BIOSTEMI Randomized Trial.
Iglesias JF, Muller O, Losdat S, Roffi M, Kurz DJ, Weilenmann D, Kaiser C, Valgimigli M, Windecker S, Pilgrim T. Iglesias JF, et al. Among authors: pilgrim t. JACC Cardiovasc Interv. 2020 Oct 12;13(19):2314-2316. doi: 10.1016/j.jcin.2020.07.038. JACC Cardiovasc Interv. 2020. PMID: 33032722 Free article. Clinical Trial. No abstract available.
Drug-eluting stent thrombosis.
Pilgrim T, Windecker S. Pilgrim T, et al. Minerva Cardioangiol. 2009 Oct;57(5):611-20. Minerva Cardioangiol. 2009. PMID: 19838151
Comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary revascularization a randomized controlled trial.
Pilgrim T, Räber L, Limacher A, Löffel L, Wenaweser P, Cook S, Stauffer JC, Togni M, Vogel R, Garachemani A, Moschovitis A, Khattab AA, Seiler C, Meier B, Jüni P, Windecker S. Pilgrim T, et al. JACC Cardiovasc Interv. 2011 Jun;4(6):672-82. doi: 10.1016/j.jcin.2011.02.017. JACC Cardiovasc Interv. 2011. PMID: 21700254 Free article. Clinical Trial.
2-year clinical follow-up from the randomized comparison of biolimus-eluting stents with biodegradable polymer and sirolimus-eluting stents with durable polymer in routine clinical practice.
Klauss V, Serruys PW, Pilgrim T, Buszman P, Linke A, Ischinger T, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, van Geuns RJ, van Es GA, Kalesan B, Wenaweser P, Jüni P, Windecker S. Klauss V, et al. Among authors: pilgrim t. JACC Cardiovasc Interv. 2011 Aug;4(8):887-95. doi: 10.1016/j.jcin.2011.03.017. JACC Cardiovasc Interv. 2011. PMID: 21851904 Free article. Clinical Trial.
Long-term comparison of everolimus- and sirolimus-eluting stents in patients with acute coronary syndromes.
Kalesan B, Stefanini GG, Räber L, Schmutz M, Baumgartner S, Hitz S, Baldinger SH, Pilgrim T, Moschovitis A, Wenaweser P, Büllesfeld L, Khattab AA, Meier B, Jüni P, Windecker S. Kalesan B, et al. Among authors: pilgrim t. JACC Cardiovasc Interv. 2012 Feb;5(2):145-54. doi: 10.1016/j.jcin.2011.11.005. JACC Cardiovasc Interv. 2012. PMID: 22361598 Free article.
The impact of anemia on long-term clinical outcome in patients undergoing revascularization with the unrestricted use of drug-eluting stents.
Pilgrim T, Vetterli F, Kalesan B, Stefanini GG, Räber L, Stortecky S, Gloekler S, Binder RK, Wenaweser P, Moschovitis A, Khattab AA, Buellesfeld L, Zwahlen M, Meier B, Jüni P, Windecker S. Pilgrim T, et al. Circ Cardiovasc Interv. 2012 Apr;5(2):202-10. doi: 10.1161/CIRCINTERVENTIONS.111.965749. Epub 2012 Mar 27. Circ Cardiovasc Interv. 2012. PMID: 22456025
416 results